Is Postprandial Glucose Control Important? Is It Practical In Primary Care Settings?
- Christopher Grainger Parkin, MS and
- Neil Brooks, MD, FAAFP
Abstract
In Brief
Large interventional studies have shown that achieving and maintaining near-normal glycemic levels reduces the risk for microvascular and macrovascular complications in type 2 diabetes. The impact of postprandial glucose on glycemic control has become a topic of much discussion among clinicians. This article examines the literature related to the role of postprandial glucose in type 2 diabetes, both as a contributor to overall glycemia and as an independent risk factor for diabetes complications, and discusses the practicality of managing postprandial hyperglycemia in primary care settings.
Footnotes
-
Christopher Grainger Parkin, MS, is a medical writer and educational consultant in Carmel, Ind. Neil Brooks, MD, FAAFP, is a private practice physician in Vernon, Conn.
-
Note of disclosure: Mr. Parkin is a paid consultant for Eli Lilly and Company and Bayer Diagnostics. Dr. Brooks sits on advisory boards for Eli Lilly and Company, Aventis Pharmaceuticals, and Pfizer Pharmaceuticals. These companies manufacture or market pharmaceutical products for the treatment of postprandial hyperglycemia.
- American Diabetes Association
